Lexaria Bioscience (NASDAQ: LEXX) CEO and chair Chris Bunka is the guest on a recent episode of the EDGE podcast. Hosted by entrepreneur and angel investor Brandon C. White, the EDGE is a podcast series focused on providing a playbook for business owners that takes a look at the inner game of building a successful business and giving listeners the edge to become smarter, healthier and richer. Lexaria Bioscience is a global innovator in drug-delivery platforms. During the interview, Bunka shared his background and the journey that led him to Lexaria. He also talked about Lexaria’s business model and the company’s focus on improving the delivery of active pharmaceutical ingredients, vitamins and minerals. In addition, he discussed Lexaria’s ongoing efforts to leverage its innovative drug-delivery platform to improve the effectiveness of orally delivered compounds. “Lexaria Bioscience is a tech company, and we provide really, really interesting solutions to the pharmaceutical industry, as well as nutraceuticals and even delivery of beneficial vitamins and minerals in foods,” said Lexaria Bioscience CEO and chair Chris Bunka in the podcast. “Our technology is all about enabling a much higher fraction and a much smoother delivery of the beneficial substances in the foods you eat and in the drugs you take and, quite frankly, getting them into your bloodstream. With a lot of these compounds and drugs, the vast majority of what you eat or swallow ends up in the toilet, and that’s no good. So we can fix that.”
To view the full interview, visit https://ibn.fm/153ow
To view the full press release, visit https://ibn.fm/I4MeO
About Lexaria Bioscience Corp.
Lexaria Bioscience’s patented drug-delivery technology, DehydraTECH(TM), improves the way active pharmaceutical ingredients (“APIs”) enter the bloodstream by promoting more effective oral delivery. Since 2016, DehydraTECH has repeatedly demonstrated the ability to increase bioabsorption with cannabinoids and nicotine by 5 to 10 times as well as reduce time of onset from one to two hours to minutes and mask unwanted tastes. The delivery systems are also being evaluated for orally administered, anti-viral drugs; nonsteroidal, anti-inflammatory drugs (“NSAIDs”); and more. DehydraTECH has also evidenced an ability to deliver some drugs more effectively across the blood brain barrier. Lexaria operates a licensed in-house research laboratory and holds a robust intellectual property portfolio with 21 patents granted and more than 50 patents pending worldwide. For more information about the company, please visit www.LexariaBioscience.com.
NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://ibn.fm/LEXX
About InvestorWire
InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.
With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.
Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.
For more information, please visit https://www.investorwire.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer
InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.investorwire.com
[email protected]
InvestorWire is part of the InvestorBrandNetwork.